24 jun: INCREASE IN MAXIMUM AMOUNT OF INSTRUMENT ISSUED BY Nordea Bank Ab..
25 jun: Indre værdi af SmallCap Danmark A/S er opgjort til 10,5 kr. pr. a..
24-06-2019 16:50:23

CORRECTING and REPLACING -- Saxena White P.A. Files Securities Fraud Class Action Against Teva Pharmaceutical Industries Ltd.

In a release issued under the same headline earlier today by Saxena White P.A., please note that in the second paragraph of the release, the deadline to file should be August 23, not August 20 as previously stated. The corrected release follows:

Saxena White P.A. Files Securities Fraud Class Action Against Teva Pharmaceutical Industries Ltd.

BOCA RATON, Fla., June 24, 2019 (GLOBE NEWSWIRE) -- Saxena White P.A. has filed a securities fraud class action lawsuit in the United States District Court for the Eastern District of Pennsylvania against Teva Pharmaceutical Industries Ltd. (“Teva”) (NYSE: TEVA) on behalf of all persons or entities who purchased or otherwise acquired Teva American Depositary Shares (“ADS”) between August 4, 2017 and May 10, 2019, inclusive (the “Class Period”).

If you purchased Teva ADS during the Class Period and wish to apply to be lead plaintiff, a motion on your behalf must be filed with the Court by no later than August 23, 2019. You may contact David Kaplan (dkaplan@saxenawhite.com), an attorney and Director at Saxena White P.A., to discuss your rights regarding the appointment of lead plaintiff or your interest in the class action. You may also retain counsel of your choice and need not take any action at this time to be a class member.

Teva is the world’s largest generic drug manufacturer. Since at least 2014, there has been intense public scrutiny into the rising prices of generic drugs, including Congressional hearings, calls for drug pricing legislation, and prosecutorial investigations.  The first such investigation was initiated by the Attorney General (“AG”) of Connecticut in July 2014.  Shortly thereafter, the United States Congress and United States Department of Justice each launched similar probes into skyrocketing prices of generic drugs.  Since that time, Teva has been subject of intense public scrutiny concerning its alleged involvement in an industry-wide price-fixing scheme and other collusive misconduct in the U.S. generic drug market. 

The Complaint asserts claims for violations of Sections 10(b) and 15 of the Securities Exchange Act of 1934 against Teva and certain of its senior executives (“Defendants”).  The action alleges that throughout the Class Period, Defendants made false and/or misleading statements denying that Teva “engaged in any conduct that would give rise to liability” in various antitrust proceedings and investigations that enveloped the company.  In truth, and as Defendants failed to disclose to investors, (i) contrary to its public denials, Teva had in fact engaged in a vast, industry-wide price-fixing scheme and other collusive misconduct since at least 2012; (ii) Teva was not only a participant, but the company at the heart of the anticompetitive scheme; and (iii) several Teva employees had such deep involvement in the scheme that they would ultimately be named personally as defendants in a sweeping civil enforcement action filed by the AGs of virtually every state in the nation.

On December 9, 2018, it was publicly disclosed that the scope of the State AGs’ investigation had expanded greatly to include 300 drugs and at least 16 companies, exposing “the largest cartel in the history of the United States.”  On this news, the price of Teva ADS fell $0.97 per share or 5%, to close at $18.44 per share on December 10, 2018.

On May 10, 2019, a coalition of 44 states filed a 524-page antitrust complaint revealing previously undisclosed facts regarding Teva’s participation in the generic drug price-fixing conspiracy.  Among other things, the action detailed Teva’s role as a “consistent participant” in the conspiracy, implementing price increases on upwards of 110 generic drugs and colluding with competitors regarding over 85 different generic drugs.  On this news, the price of Teva ADS fell $2.13 per share or approximately 15%, to close at $12.23 per share on May 13, 2019.   

You may obtain a copy of the Complaint and join the class action at www.saxenawhite.com.

Saxena White P.A., with offices in Florida, New York, and California, concentrates its practice on prosecuting securities fraud and complex class actions on behalf of institutions and individuals. Currently serving as lead counsel in numerous securities fraud class actions nationwide, the firm has recovered hundreds of millions of dollars on behalf of injured investors and is active in major litigation pending in federal and state courts throughout the United States.

CONTACT INFORMATION

David Kaplan, Esq.

dkaplan@saxenawhite.com

Saxena White P.A.

12750 High Bluff Drive, Suite 475

San Diego, CA 92130

Tel: (858) 987-4073

Fax: (858) 369-0096

www.saxenawhite.com

 

SW Logo.PNG

Relateret indhold
Relateret debat
21 jul - 
Det bliver svært at bevise at det var medicinalfirmaern..
21 jul - 
Meget enig. Derudover kan nævnes at goodwill og immater..
21 jul - 
Lidt forenklet kan man sige, at de har købt et andet fi..
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
20 jul
TEVA
Henningmaria: Casen omkring Teva har ikke ændret sig fundamentalt blot folks følelser pga verserende..
14
17 jul
TEVA
Har aldrig helt forstået de her “hvad sagde jeg”-tråde. Shortede du Teva da KS trådte til? Ellers vi..
9
20 jul
TEVA
der er som bekendt mange danskere som har tabt mange penge på Teva siden Kåre Schultz kom til som ad..
4
17 jul
TEVA
Når nu vi snart ser TEVA mellem kurs 6 og 4 USD er det min vurdering den er købsmoden. Så er der kun..
4
21 jul
TEVA
Lidt forenklet kan man sige, at de har købt et andet firma for penge de har lånt. Det er penge som s..
3
20 jul
TEVA
Jo, det er jo altsammen rigtigt, men indtjeningen skal jo ikke skuffe meget før de løber ind i probl..
3
21 jul
TEVA
Det bliver svært at bevise at det var medicinalfirmaernes skyld. Problem number one: In the practic..
2
17 jul
TEVA
hej tdt123 godt at høre fra dig, KS er gammel mckinsey mand det skal man aldrig undervurdere, det er..
2
17 jul
TEVA
Hehe tror nu ikke vi skal give KS skylden for karteldannelse og andre lig, de var ellers godt på vej..
2
21 jul
TEVA
Meget enig. Derudover kan nævnes at goodwill og immaterielle aktiver, som er det medicin firmaer har..
1

Fondsbørsmeddelelser

Euroinvestor spørger: Bliver Trump genvalgt i 2020 og har Amazon overhalet alle andre om ét år?

23-07-2019 20:23:36
Relaterede nyheder
Hos Euroinvestor mener vi, at den bedste kilde til viden om markedet er aktørerne i markedet. Derfor spørger vi hver måned i vores Privatinvestorundersøgelse (PIU) vores brugere om deres forventninger til markeder og økonomi. Du inviteres hermed til at deltage i undersøgelsen. Alle besvarelser er anonyme, og der er ingen krav om login, kontaktoplysninger eller lignende. Vi håber du vil deltage og ..

Genmab/Nordnet: Penge fra USA-notering ryger nok i udviklingsreserver

23-07-2019 12:25:21
Mandag gennemførte Genmab salget af flere millioner aktier i forbindelse med sin børsnotering i USA, og det indbragte selskabet frisk kapital, som formentlig vil blive lagt til side til fremtidige udviklingsprojekter.Sådan lyder vurderingen fra Per Hansen, investeringsøkonom hos børsmægleren Nordnet, om de godt 3,4 mia. kr., som Genmab har rejst i bruttoprovenu ved salget af 2,85 mio. nye aktier p..

Aktier/tendens: Udenlandsk udvikling bliver afgørende for DSV og andre

23-07-2019 08:22:55
Der er ikke meget fra det hjemlige at tage bestik af på det danske aktiemarked tirsdag morgen.Dermed bliver det den udenlandske udvikling, heriblandt et hæderligt regnskab fra DSV-kollegaen Kuehne+Nagel, der kommer til være bestemmende for retningen fra handlens start tirsdag.De ledende amerikanske aktieindeks sluttede mandag med plusser, og de asiatiske markeder har fulgt op på udviklingen med st..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Danmark/økonomer: Forbrugerne aner uråd
2
Veloxis/Kempen: Kursmålet løftes med 20 pct.
3
Aktier/tendens: Udenlandsk udvikling bliver afgørende for DSV og andre
4
Professor om Johnsons brexitplan: Han er kravlet op i et træ - NY
5
NKT får ordre på højspændingskabler til Viking Link - NY

Relaterede aktiekurser


Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
23. juli 2019 22:11:52
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190703.1 - EUROWEB3 - 2019-07-23 22:11:52 - 2019-07-23 22:11:52 - 1 - Website: OKAY